Transatlantic Medical Corp is looking to ramp up production of its improved COVID-19 respirators. It expects this project to have the following incremental income statement and incremental pro-forma partial balance sheet: Fiscal Year 2020 2021 2022 2023 Incr. Income Revenues 20.1 56.7 69.6 61.8 Costs 12.5 34.8 42.7 37.9 Assets Inventories Acc Receivable 1.2 0.6 2.8 1.3 3.5 1.6 3.1 1.4 Liabilities Accounts Payable R 1.2 2.0 2.5 2.2 * All figures are in millions of dollars. The project will begin in 2020 with a capital expenditure of $18 million. Follow up capital expenditures of $2 million, $3 million, and $1 million are expected in 2021, 2022, and 2023 respectively. All capex is fully depreciable to zero salvage value over 4 years on a straight-line basis. The marginal tax rate for the project is 36.0%. What is the expected incremental cash flow from the COVID-19 respirators project in 2023? million (Give answer to 2 decimal places)